Efficacy of CystoneÂ® versus Tamsulosin in treatment of Stent-Related Lower Urinary Tract Symptoms

CystoneÂ® versus Tamsulosin on Stent-Related Lower Urinary Tract Symptoms

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200705001

Enrollment

Unknown

Registered

2020-07-05

Start date

2017-07-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Double&#45

Interventions

Tamsulosin 0.4 mg tablet daily before the implementation of the procedure for 4 weeks,Cystone (this drug has one shape and single dose) tablet every 8 hours before the implementation of the procedure

Experimental Drug,Experimental Drug,Experimental Drug,Placebo Comparator Drug

Tamsulosin ,Cystone ,Tamsulosin + Cystone (n,Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria were the patients who underwent a unilateral Trans Ureteral Lithotripsy (TUL).

Exclusion criteria

Exclusion criteria: Patients with bilateral Ureteral stone,history of Renal failure, anatomical or functional urological abnormality were excluded.

Design outcomes

Primary

Measure	Time frame
Double-J Stent-Related Lower Urinary Tract Symptoms Before stent insertion, after 2 weeks, and after 4 weeks The IPSS (International Prostate Symptopm Score)	—

Secondary

Measure	Time frame
Pain Before stent insertion, after 2 weeks, and after 4 weeks Visual analogue scale	—

Countries

Iran

Contacts

Public ContactMohammadali Ghaed

Department of Urology, Iran University of Medical Sciences, Akbarabadi Teaching Hospital, Tehran, Ir

m.ghaed2020@gmail.com00983833330061

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Efficacy of CystoneÂ® versus Tamsulosin in treatment of Stent&#45;Related Lower Urinary Tract Symptoms